

Corp. Off.:- 201, "The Summit Business Bay" Behind Guru Nanak Petrol Pump, Off Andheri Kurla Road, Andheri (E), Mumbai - 400 093 (India)

Ph.: +91 22 69073100

May 18, 2024

BSE Limited

Phiroze Jeejeebhoy Towers Dalal Street Mumbai-400001

Scrip Code: 533543

Sub: Outcome of Board Meeting

National Stock Exchange of India Ltd.

Exchange Plaza, C-1, Block G Bandra Kurla Complex Bandra (E), Mumbai-400051

Symbol: BROOKS

Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")

Dear Sir/Madam,

This is to inform you that the Board of Directors of the Company in its Meeting held on Saturday, May 18, 2024 have discussed and approved the Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ending March 31, 2024.

In this regard, we are enclosing herewith the following:

- 1. Audited Standalone and Consolidated Financial Results of the Company for the quarter and financial year ended on March 31, 2024 along with the Auditor's Report thereto
- 2. Declaration on Unmodified Opinion in the Auditor's Report for Financial Year 2023-2024;

The Board Meeting commenced at 3:00 P.M and concluded at 5.10 P.M.

We request you to kindly take the same on record.

Thanking You,
Yours faithfully
For BROOKS LABORATORIES LIMITED

Jai Vaidya Company Secretary

Encl.: As Stated

Regd. Off & Works: Village Kishanpura, Baddi Nalagarh Road, Baddi (H.P.) - 174101 (India) Tele Fax .: 01795 236939 (CIN NO: L24232HP2002PLC000267), E-mail: investors@brookslabs.net, Website: www.brookslabs.net

Brooks Laboratories Limited
Ragd Office: Village Kishanpura, Nalagarh Road, Baddi, Dist. Solan H.P.-174101
CIN NO: L24232HP2002PLC000267

E-mail: investors@brookslabs.net | Website: www.brookslabs.net

Statements of Audited Financial Results for the Quarter and Year Ended 31st March 2024

Particulars	Standalone Consolidated								DESCRIPTION OF THE PARTY OF THE	(Rs. In Lakhs)	
	Quarter Ended			Year ended			Quarter Ender		Year ended		
数据的表示的特别的现在分词的现在分词	31-Mar-24	31-Dec-23	31-Mar-23	31-Mar-24	31-Mar-23	31-Mar-24	31-Dec-23	31-Mar-23	31-Mar-24	31-Mar-23	
	Audited	Unaudited	Audited	Audited	Audited	Audited	Unaudited	Audited	Audited	Audited	
1 Income	141141	1					7/4/7/7				
	4 770 47	0.474.00	4 204 44	701001	F FF0 00						
Revenue from operations Other Income	1,772.17	2,174.66	1,261.41	7,948.61	5,553.80	1,772.17	2,174.66	1,261.41	7,948.61	6,320.46	
Total income	65.36 1,837.53	15.50	1,264.13	95.55 8,044.16	11.53 5,565,33	65.36 1,837.53	15.50 2.190.16	1.264.13	95.55 8.044.16	6.341.61	
Town moons	1,007.00	2,100.10	1,204.10	0,044.10	0,000.00	1,007.00	2, 100.10	1,204.13	0,044.10	0,341.01	
2 Expenses				100							
(a) Cost of materials consumed	974.21	1,208.56	833.55	4,472.28	3,232.84	974.21	1,208.56	833.55	4,472.28	4,154.53	
(b) Purchase of Stock in Trade	311.09	289.95	58.66	1,049.82	611.99	311.09	289.95	58.66	1,049.82	487.24	
(c) Change in inventories of finished goods, work-in-progress and stock-in-trade	(13.35)	47.33	(71.63)	139.80	200.90	(13.35)	47.33	(71.63)	139.80	418.45	
(d) Employees benefits expenses	227.58	283.92	226.22	1,054.06	1,154.12	227.58	283.92	226.22	1,054.06	1,734.16	
(e) Finance Costs	27.43	21.29	18.43	84.49	76.67	27.43	21.29	18.43	84.49	218.32	
(f) Depreciation and amortization expenses	45.63	43.48	43.55	177.33	171.74	45.63	43.48	43.55	177.33	702.68	
(g) Other expenses	234.60	235.28	226.54	910.92	935.38	234.60	235.28	226.54	910.92	2,167.91	
Total Expenses	1,807.19	2,129.81	1,335.32	7,888.70	6,383.64	1,807.19	2,129.81	1,335.32	7,888.70	9,883.29	
3 Profit/(Loss) before Share of Profit / (Loss) of Associate,	30.34	60.35	(71.19)	155.46	(818.31)	30.34	60.35	(71.19)	155.46	(3,541.68	
exceptional item and tax	V4121	15000									
4 Share of Profit / (Loss) from Jointly controlled entities and associates			-	-		(990.94)	(445.62)	(357.85)	(2,112.06)	(330.99	
Profit/(Loss) before Exceptional item and tax	30.34	60.35	(71.19)	155.46	(818.31)	(960.60)	(385.27)	(429.04)	(1,956.60)	(3,872.67	
5 Exceptional items	-		-			-	-	-		(35.67	
6 Profit/(Loss) from ordinary activities before tax 7 Tax Expense:	30.34	60.35	(71.19)	155.46	(818.31)	(960.60)	(385.27)	(429.04)	(1,956.60)	(3,837.00	
Deferred Tax Liability / (Assets)(Refer note 6)							- 1		Marian P.	(732.40	
MAT credit reversal	-			-			- 1	0.00			
Tax of earlier years	-	2.59	-	2.59		-	2.59	-	2.59	-	
8 Net Profit/(loss) after tax	30.34	57.76	(71.19)	152.87	(818.31)	(960.60)	(387.86)	(429.04)	(1,959.19)	(3,104.60	
9 Other Comprehensive income items That will not be reclassified into Profit or loss											
Actuarial Gain/ (Loss) on Defined Benefit Plans (Net of Tax)	(4.33)		(4.10)	(4.33)	(4.10)	(4.33)		(4.10)	(4.33)	(4.10	
Gain on remeausring FVTPL financial assets	26.01	57.76	(75,29)	148.54	(822,41)	(964,93)	(387,86)	(433,14)	(1,963.52)	(3,108.70	
0 Total Comprehensive income for the period Net Profit attributable to	26.01	57.76	(/5.29)	148.54	(822.41)	(964.93)	(387.80)	(433.14)	(1,963.52)	(3,108.70	
Owners of equity						(960.60)		(429.85)	(1,959.19)	(2.089.19	
Non Controlling Interest		(A)				(300.00)		(425.00)	(1,000.10)	(1,015.41	
Other Comprehensive Income attributable to :										(1,010,41	
Owners of equity	122	0.1		125		(4.33)		(3.29)	(4.33)	(4.10	
Non Controlling Interest						(4.55)		(0.20)	(1.00)	, , , ,	
Total Comprehensive income attributable to							Vo. 0 = 1				
Owners of Equity							- 1	(433, 14)		(2.093.29	
Non Controlling Interest								-		(1,015.41	
1 Paid-up equity share capital (Face Value of Rs. 10 each)	2,624.67	2,624.67	2,470.28	2,624.67	2,470.28	2,624.67	2,624.67	2,470.28	2,624.67	2,470.28	
2 Reserves (excluding Revaluation Reserve) as shown in the Audited		3,207.61	4,030.03	3,207.61	4,030.03	4,925.05	4,925.05	6,278.72	4,925.05	6,278.72	
Balance Sheet of previous year.											
3 Earnings per share (of Rs. 10/- each)				C 1 1 1							
(not annualised)											
(a) Basio	0.10	0.23	(0.29)	0.58	(3.32)	(3.77)	(1.51)	(1.74)	(7.67)	(12.57	
(b) Diluted	0.10	0.23	(0.29)	0.58	(3.32)	(3.77)	(1.51)	(1.74)	(7.67)	(12.57	

Place : Baddi Date : 18th May 2024

- 1 The above Financial Results of the Company have been reviewed by the Audit committee and approved by the Board of Directors at their respective meeting held on May 18, 2024
- 2 The financial results have been prepared in accordance with Indian Accounting Standard ("Ind AS") prescribed under section 133 of the Companies Act 2013, read with relevent rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015 (as amended) and SEBI Circular Dated 5th July, 2016
- 3 The Board of Directors at its meeting held on July 18, 2023, has inter alia considered and approved the rights issue of 15,43,926 fully paid-up Equity Shares at issue price of Rs. 75 per equity share [including a premium of Rs. 65 per Equity Shares] for amount aggregating up to Rs. 1,157.94 lakhs. Subsequently, Rights issue Letter of Offer (LoF) was filed on August 1, 2023 with BSE Limited (BSE). August 2, 2023 with National Stock Exchange of India Limited (NSE) and August 3,2023 with Securities and Exchange Board of India (SEBI). The company has alloted the shares on August 28, 2023. The Right Issue proceeds were fully utilised for objects mentioned in Letter of offer dated July 18, 2023.
- 4 The Consolidated Financial Results have been prepared in accordance with Ind AS 110 on "Consolidated Financial Statements" and Ind AS 28 on "Investments in Associates and Joint Ventures".
- 5 During the quarter ended December 31, 2022 the company has lost control over its own subsidiary company Brooks Steriscience Limited (BSL). The company now jointly controls the entity along with its JV partner and has accounted accordingly subsequent to loss of control. Hence the current year consolidated figures are not comparable with previous year consolidated figures.
- 6 In the absence of future taxable profit, The Holding Company has not recognised deferred tax asset on its business losses/depreciation in accordance with Ind As 12" Income taxes"
- 7 The Company operates in one reportable business segment i.e * Pharmaceuticals*.
- 8 Figures of the previous reporting quarter/year has been reclassified/ regrouped wherever necessary to correspond with the figures of the current quarter/year.

For and on Behalf of the Board Before

Baddi - 174101

INDIA.

Bruthan Singh Rana Diry 10289384

Whole Time Director

Brooks Laboratories Limited

Regd Office: Village Kishanpura, Nalagarh Road, Baddi, Dist. Solan H.P.-174101

CIN NO: L24232HP2002PLC000267

E-mail: investors@brookslabs.net | Website: www.brookslabs.net

Statement of Assets & Liabilities as at 31st March, 2024

(Rs. In Lakhs)

		Stand	Conso	lidated	
	Particulars	As at March 31, 2024 (Audited)	As at March 31, 2023 (Audited)	As at March 31, 2024 (Audited)	As at March 31, 2023 (Audited)
A	ASSETS				
1	Non Current Assets				
	(a) Property, Plant and Equipment	1,307.22	1,401.53	1,307.22	1,401.5
	(b) Capital work in progress				1,101.0
	(c) Right to use Assets	52.79	79.36	52.79	79.3
	(d) Intangible asset	7.31	19.88	7.31	19.8
	(e) Intangible asset under Development		10.00	7.01	10.0
	(f) Financial Assets			2116	
	(i) Investments	4,685.95	4.685.16	4,291.33	6,402.6
	(ii) Security deposits	42.95	31.57	42.95	31.5
	(ii) Other Financial Assets	13.31	16.85	13.31	16.8
	(g) Income Tax Assets (Net)	224.80	247.31	224.80	
	(h) Deferred tax asset (net)	224.00	247.31	224.60	247.3
	(i) Other Non Current Assets			uple - 1	
	Total Non - Current Assets	6,334.33	6 404 66	5.020.74	0.400.4
		0,334.33	6,481.66	5,939.71	8,199.1
2	Current assets				
	(a) Inventories	961.08	1,130.32	961.08	1,130.3
	(b) Financial Assets				
	(i) Trade receivables	1,631.62	1,275.42	1,631.62	1,275.4
	(ii) Cash and Cash Equivalents	12.55	2.32	12.55	2.3
	(iii) Bank Balances other than cash & cash equivalents	56.79	105.21	56.79	105.2
	(iv) Security deposit	11.58		11.58	
	(v) Other Financial Assets	176.51	30.29	176.51	30.2
	(c) Other Current Assets	254.70	217.07	254.70	217.0
	Total Current Assets	3,104.83	2,760.63	3,104.83	2,760.63
	TOTAL ASSETS	9,439.16	9,242.29	9,044.54	10,959.73
В	EQUITY AND LIABILITIES				
1	Equity			医沙丘耳 人	
	(a) Equity Share Capital	2.624.67	2,470.28	2.624.67	2,470.2
	(b) Other Equity	4,328.48	3,207.61	3,933.86	4,925.0
	Equity attributable to Owners of the Company	6,953.15	5,677.89	6,558.53	7,395.3
	Non-Controlling interests		-	- 1	-
	Total Equity	6,953.15	5,677.89	6,558.53	7,395.3
	Liabilities				
2	Non-current liabilities				
	(a) Financial Liabilities			3145	
	(i) Lease Liability	35.65	60.22	35.65	60.2
	(ii) Other Financial Liabilities	53.06	55.93	53.06	55.9
	(b) Provisions	92.54	146.12	92.54	146.1
	Total Non - Current Liabilities	181.25	262.27	181.25	262.2
3	Current liabilities	101,00			
0	(a) Financial Liabilities				
	(i) Borrowings	504.20	566.35	504.20	566.3
		24.34	24.65	24.34	24.6
	(ii) Lease liability	24.34	24.00	24.34	24.0
	(iii) Trade Payables	704.00	074.45	794.69	871.1
	- Due to micro and small enterprises	794.69	871.15		
	- Due to Others	749.64	1,465.89	749.64	1,465.8
	(iv) Other Financial Liabilities	116.64	127.85	116.64	127.8
	(b) Other current liabilities	51.22	114.44	51.22	114.4
	(c) Provisions	64.03	131.80	64.03	131.8
	Total Current Liabilities	2,304.76	3,302.13	2,304.76	3,302.13
	TOTAL EQUITY AND LIABILITIES	9,439.16	9,242.29	9,044.54	10,959.73

Place : Baddi Date : 18th May 2024 Bhushan Singh Rana Din: 10289384 Whole Time Director

For Brooks Laboratories Limited

mited aborato

Vill.-Kishenpura on Baddi – 174101.

Brooks Laboratories Limited

Place : Baddi

Date: 18th May 2024

Regd Office: Village Kishanpura, Nalagarh Road, Baddi, Dist. Solan H.P.-174101

CIN NO: L24232HP2002PLC000267

E-mail: investors@brookslabs.net | Website: www.brookslabs.net

Cash Flow Statement for the period ended 31st March, 2024

(Rs. In Lakhs)

	Standa	THE RESIDENCE OF THE PARTY OF T	Consolidated		
Particulare	Year ended 31 March 2024	Year ended 31 March 2023	Year ended 31 March 2024	Vear ended 31 March 202	
第二十二十二十二十二十二十二十二十二十二十二十二十二十二十二十二十二十二十二十	Audited	Audited	Audited	Audited	
A. CASH FLOW FROM OPERATING ACTIVITIES					
Net (loss) / profit before tax	155.46	(818.31)	(1,956.60)	(3,837.00	
Adjustments for		,	(1,000.00)	(0,001.101	
Depreciation and amortisation expense	177.33	171.74	177.33	702.68	
Finance cost	84.49	76.67	84.49	218.32	
Interest income	(7.36)	(7.22)	(7.36)	(9.2	
Notional Income from corporate guarantee in favour of associate	(2.95)	(3.10)	(2.95)	(3.10	
Gain on revaluation of investment	(0.79)	(0.81)	(0.79)	(0.81	
Commission on corporate guarantee	(65.00)		(65.00)		
Gain on Loss of Control				(35.67	
Share of Profit / (loss) of Associates and Joint Venture			2,112.06	330.99	
Dividend from current investments	(0.40)	(0.40)	(0.40)	(0.40	
Sundry Balances written back	(3.73)	-	(3.73)	19.06	
Provision/(reversal) for Expected credit loss	(15.86)	38.63	(15.86)	38.65	
Unrealised Foreign Exchange Gain	(2.01)	0.05	(2.01)	0.05	
Operating profit before working capital changes	319.18	(542.75)	319.18	(2,576.44	
Adjustments for changes in working capital:					
Decrease / (increase) in Trade Receivables	(338.34)	189.43	(338.34)	(268.73	
Decrease / (increase) in Inventories	169.23	528.45	169.23	328.60	
Decrease / (increase) in Other Assets	(37.63)	82.68	(37.63)	(227.80	
Decrease / (increase) in Other Financial Assets	(171.57)	153.67	(171.57)	134.53	
(Decrease) / Increase in Trade and Payables	(788.94)	(237.69)	(788.94)	1,083.78	
(Decrease) / Increase in Other Financial Liabilities	49.00	(31.18)	49.00	(34.35	
(Decrease) / Increase in Other Liabilities	(63.22)	(103.50)	(63.22)	47.29	
(Decrease) / Increase in Provisions	(125.69)	35.02	(125.69)	79.36	
Cash generated from / (used in) operations	(987.98)	74.13	(987.98)	(1,433.76	
Direct taxes paid (net of refunds received)	19.92	(19.28)	19.92	(15.26	
Net cash (used in) / from generated from operating activities	(968.06)	54.85	(968.06)	(1,449.02	
B. CASH FLOW FROM INVESTING ACTIVITIES					
Purchase of property, plant and equipment	(43.90)	(46.75)	(43.90)	(46.75	
Net (investments in)/ proceeds from bank deposits (having original maturity of more			1	,	
than three months)	51.97	(0.84)	51.97	86.62	
Interest received	9.74	7.33	9.74	9.21	
Dividend received	0.41	0.40	0.41	0.40	
Net cash (used in) / generated from investing activities	18.22	(39.86)	18.22	49.48	
C. CASH FLOW FROM FINANCING ACTIVITIES					
Proceeds by Minority Interest				1,762.90	
Proceeds by Millionly Interest Proceeds/ (Repayment) from borrowings (net)	(62.15)	74.05	(62.15)	(383.52	
Proceeds from Issue of Equity Shares (Including premium net off issue related	(02.10)	74.00	(02.10)	(000.02	
expense)	1,126.72		1,126.72		
Repayment of Lease Liabilities	(24.88)	(19.70)	(24.88)	(19.70	
	(79.62)	(75.40)	(79.62)	(218.32	
Finance costs paid	(75.02)	(75.40)	(10.02)		
Net cash (used in) / from financing activities	960.07	(21.05)	960.07	1,141.36	
Net increase / (decrease) in cash and cash equivalents	10.23	(6.06)	10.23	(258.18	
Cash and cash equivalents at the beginning of the year	2.32	8.38	2.32	260.50	
Cash and cash equivalents at the end of the year	12.55	2.32	12.55	2.32	
Cash and cash equivalents at the end of the year	12.00	2.02	72.00		

For and on Behalf of Board 135 ferne

Bhushan Singh Rana Din: 10289384

Wholetime Director

aborato Vill.-Kishangura Baddi - 174101. INDIA.

SGCO & Co.LLP Chartered Accountants

Independent Auditors' Report on the Quarterly and Year to Date Audited Standalone Financial Results of Brooks Laboratories Limited pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
The Board of Directors of
Brooks Laboratories Limited

Opinion

We have audited the accompanying statement for the quarterly and year to date standalone financial results of Brooks Laboratories Limited (the "Company") for the quarter ended March 31, 2024 and for the year ended March 31, 2024 (the "Statement"), attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the Statement:

- i. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards and other accounting principles generally accepted in India of the net profit, other and total comprehensive income and other financial information for the quarter and year ended March 31, 2024.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under Section 143(10) of the Companies Act, 2013, as amended (the "Act"). Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the Standalone Financial Results" section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the standalone financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.

Management and Board of Directors' Responsibilities for the Standalone Financial Results The Statement have been prepared on the basis of the standalone annual financial statements.

The Company's Management and the Board of Directors is responsible for the preparation and presentation of the Statement that give a true and fair view of the net profit, other and total comprehensive income and

4A, Kaledonia, 2nd Floor, Sahar Road, Near Andheri Station, Andheri (East), Mumbai - 400 069 Tel. +91 22 6625 6363 Fax. +91 22 6625 6364 E-mail. info@sgco.co.in www.sgco.co.in





other financial information in accordance with the applicable Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Statement by the Board of Directors.

In preparing the Statement, the Management and Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Management and the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Management and the Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditors' Responsibilities for the Audit of the Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that
 are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for
 expressing our opinion through a separate report on the complete set of financial statements on whether



SGCO & Co.LLP

Chartered Accountants

the Company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the Statement made by the Board of Directors.
- Include on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters

The Statement includes the figures for the last quarter of the current and previous financial year are the balancing figures between audited figures in respect of the full financial years and the published year to date figures up to the end of third quarter of the current and previous financial year.

Our opinion is not modified in respect of these matters.

For S G C O & Co. LLP

Chartered Accountants

Firm Registration Number: 112081W/W100184

Suresh Murarka

Partner

Mem No: 044739

UDIN: 24044739 BKARKW1459

Place: Mumbai Date: 18th May 2024

SGCO & Co.LLP Chartered Accountants

Independent Auditors' Report on the Quarterly and Year to Date Consolidated Financial Results of Brooks Laboratories Limited Pursuant to the Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To
The Board of Directors of
Brooks Laboratories Limited

Opinion

We have audited the accompanying Statement of quarterly and year to date Consolidated Financial Results of Brooks Laboratories Ltd. ("Holding Company") and its Jointly controlled entity and its associates for the quarter ended March 31, 2024 and for the year ended March 31, 2024 (the "Statement"), attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the reports of the other auditors on separate audited financial statements of Jointly controlled entities and associates, the aforesaid Statement:

- a. include the financial results of the following entities:
 - Brooks Laboratories Limited (Holding Company)
 - 2. Brooks Steriscience Limited (Jointly controlled Entity)
 - 3. Steribrooks Penems Private Limited (Associate Company)
- are presented in accordance with the requirements of Regulations 33 of the Listing Regulations in this regard; and
- c. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information for the year ended March 31, 2024.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("the SAs") specified under Section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those Standards are further

4A, Kaledonia, 2nd Floor, Sahar Road, Near Andheri Station, Andheri (East), Mumbai - 400 069 Tel. +91 22 6625 6363 Fax. +91 22 6625 6364 E-mail. info@sgco.co.in www.sgco.co.in





described in the "Auditor's Responsibilities for the Audit of the Consolidated Financial Results" section of our report. We are independent of the Company, its jointly controlled entity, and its associates in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us and other auditors in terms of their reports referred to in "Other Matter" paragraph below, is sufficient and appropriate to provide a basis for our opinion.

Management and Board of Directors' Responsibilities for the Consolidated Financial Results

The Statement have been prepared on the basis of the consolidated annual financial statements.

The Holding Company's Management and Board of Directors are responsible for the preparation and presentation of these Statement that give a true and fair view of the net profit and other comprehensive income and other financial information of the Group including its associates in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulations 33 of the Listing Regulations. The respective Management and the Board of Directors of the entities included in the Group, of its jointly controlled entity and of its associates are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of their respective entities and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Statement by the Management and Directors of the Holding Company, as aforesaid

In preparing the Statement, the respective Board of Directors of the companies included in the Group and of its associates are responsible for assessing the ability of the respective entities to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group, of its jointly controlled entity and of its associates are responsible for overseeing the financial reporting process of their respective entities.





Auditors' Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with the SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

As part of an audit in accordance with the SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- i. Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- ii. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the Company has adequate internal financial controls with reference to financial statements in place and operating effectiveness of such controls.
- iii. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- iv. Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group and its associates to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Group and its associates to cease to continue as a going concern.
- v. Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.





vi. Obtain sufficient appropriate audit evidence regarding the financial results/ information of the entities within the Group and its associates to express an opinion on the consolidated financial results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the consolidated financial results of which we are the independent auditors. For the other entities included in the consolidated financial results, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

We communicate with those charged with governance of the Holding Company and the respective auditors communicate with those charged with governance of such other entities included in the Statement of which other auditors are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the Circular No. CIR/CFD/CMD I/44/2019 dated March 29, 2019 issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.

Other Matters

- a. The Statement includes the audited financial results of its jointly controlled entity, Brooks Steriscience Limited, whose financial statements include the group share of net loss of Rs. 991.02 lakhs and net loss of Rs. 2,111.75 lakhs for the quarter and year ended March 31, 2024, respectively, as considered in the Statement, which have been audited by its independent auditor. The independent auditor reports on financial statements of this entity have been furnished to us by the Management and our opinion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this jointly controlled entity, is based solely on the report of such independent auditor and the procedures performed by us are as stated in the "Responsibilities of the Auditors for the Audit of the Consolidated Financial Result" section of this report.
- b. The Statement also includes the unaudited financial results of its associate Steribrooks Penems Private Limited, whose financial statements reflect Group's share of total net profit of Rs. 0.09 lakhs and net loss of Rs. 0.31 lakhs for the guarter and year ended March 31, 2024, respectively as considered in the



SGCO&Co.LLP

Chartered Accountants

Statement which has not been audited and have been furnished to us by the Management.

c. The Statement includes the figures for the last quarter of the current and previous financial year are the balancing figures between audited figures in respect of the full financial years and the published year to date figures up to the end of third quarter of the current and previous financial year.

Our opinion is not modified in respect of these matters.

For S G C O & Co. LLP

Chartered Accountants

Firm Registration Number: 112081W/W100184

Suresh Murarka

Partner

Mem No: 044739

UDIN: 24044739BKARKY5147

Place: Mumbai Date: 18th May 2024



Corp. Off.:- 201, "The Summit Business Bay" Behind Guru Nanak Petrol Pump, Off Andheri Kurla Road, Andheri (E),

Mumbai - 400 093 (India) Ph.: +91 22 69073100

May 18, 2024

BSE Limited

Phiroze Jeejeebhoy Towers Dalal Street Mumbai-400001

Scrip Code: 533543

National Stock Exchange of India Ltd.

Exchange Plaza, C-1, Block G Bandra Kurla Complex Bandra (E), Mumbai-400051

Symbol: BROOKS

Sub: Declaration regarding Unmodified opinion on Audited Financial Statements.

Dear Sir/Madam,

Pursuant to Regulation 33(3) (d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby confirm and declare that the Statutory Auditors of the Company, SGCO & Co. LLP, Chartered Accountants, have issued Audit Report with Unmodified opinion on Audited Financial Results (Standalone and Consolidated) for the financial year ended March 31, 2024.

We request you to kindly take the same on record.

Thanking You,
Yours faithfully
For BROOKS LABORATORIES LIMITED

Durga Shankar Maity Whole Time Director DIN: 03136361